A Novel Approach
In a remarkable development, a research team from the Indian Institute of Science Education and Research (IISER) Mohali has identified a groundbreaking
potential treatment for dengue fever, drawing inspiration from an unexpected source: the camel. This pioneering work, spearheaded by Dr. Sharvan Sehrawat, focuses on leveraging a unique class of antibodies found in camels, known as nanobodies. These miniature yet exceptionally robust protein fragments have demonstrated an impressive ability to neutralize all four distinct strains of the dengue virus. This discovery holds significant promise for India, which grapples with a substantial dengue burden, experiencing approximately 60 lakh infections annually, representing nearly a third of the global total. The study, notably published in Immuno Horizons, marks a significant achievement as the first of its kind in India, offering a potential remedy for a disease that often resurfaces, particularly following monsoon seasons. Dengue presents a unique challenge in that a prior infection with one strain does not confer immunity; rather, a subsequent infection with a different strain can lead to more severe outcomes. This phenomenon, termed Antibody-Dependent Enhancement (ADE), occurs when antibodies from an initial infection inadvertently facilitate the entry of a new viral strain into human cells, escalating the risk of serious complications such as internal bleeding and shock syndrome. This immunological paradox has long presented a formidable obstacle in the global pursuit of effective dengue vaccines.
Camel's Unique Advantage
Camels possess a fascinating biological characteristic: their immune systems naturally produce antibodies that can be readily modified into highly specialized structures called 'single-domain antibodies,' or more commonly, nanobodies. These nanobodies are fundamentally different from the larger, more complex antibodies found in humans. They are essentially pared down to their most essential virus-fighting components, featuring a significantly simpler structure. A key distinction is their lack of an 'Fc region,' a specific segment of conventional antibodies that is implicated in triggering the harmful ADE effect. Dr. Sehrawat elaborates that the absence of this particular component makes nanobodies inherently safer, as they do not contribute to the disease's enhancement. Furthermore, their smaller size and inherent resilience allow nanobodies to access and engage with viral targets that might be inaccessible to larger human antibodies. The IISER team's research involved the creation of an extensive 'molecular library,' comprising over 200 million unique antibody sequences derived from camel samples. This vast repository enabled the researchers to meticulously search for and identify a specific nanobody that effectively binds to the dengue virus's 'envelope protein.' This protein acts as the virus's key to unlock human cells, and by obstructing this interaction, the nanobody successfully halts the infection process.
Promising Trial Results
The efficacy of these camel-derived nanobodies has been rigorously tested in laboratory settings and subsequent animal trials, yielding astonishingly positive outcomes. In experiments involving mice infected with lethal doses of dengue, the nanobody treatment led to complete recovery. The research demonstrated a significant reduction in viral loads among the treated subjects, and crucially, it effectively prevented inflammation in vital organs. A notable aspect of these findings is the absence of any adverse reactions reported during the trials, a significant advantage when compared to certain existing experimental treatments. The IISER team is now focused on the critical next phase: developing methods for large-scale production of these nanobodies. Rather than relying on expensive, sophisticated industrial facilities, they are exploring an innovative approach known as 'molecular farming.' This involves cultivating the nanobodies within plants. The researchers have already achieved success in growing these therapeutic proteins in laboratory plants such as tobacco and Arabidopsis. The ultimate ambition, however, is to shift this production to more common fruits like bananas. Dr. Sehrawat explains that plants offer rapid biomass generation, which could enable the future harvesting of these medicines directly from fruits. This method has the potential to dramatically reduce production costs, making the treatment far more affordable and accessible to a broader population. While the initial version of the treatment requires daily administration, the IISER team is actively working on a 'bivalent' version. This advanced therapy aims to involve a single injection of a super-antibody into dengue patients, representing a significant improvement in convenience and delivery.
Future Production Pathways
The journey from laboratory discovery to widespread accessibility is a crucial one, and the IISER team is actively charting the path forward for the mass production of their promising dengue nanobody treatment. Their innovative strategy centers on 'molecular farming,' a concept that moves away from traditional, high-cost pharmaceutical manufacturing. Instead, the researchers are successfully engineering common plants to act as bio-factories for these therapeutic nanobodies. Initial successes have been observed with plants like tobacco and Arabidopsis, where these proteins can be cultivated. However, the long-term vision involves utilizing readily available fruits, such as bananas, for large-scale cultivation. This approach leverages the rapid growth and high biomass production capabilities of plants, as highlighted by Dr. Sehrawat. The prospect of harvesting these life-saving medicines from everyday fruits could fundamentally transform the accessibility and affordability of dengue treatment for communities worldwide. Furthermore, the research team is not resting on its initial achievements. While the first-generation nanobody treatment has proven effective, it necessitates daily dosing. To address this, efforts are underway to develop a more advanced 'bivalent' version of the therapy. This next-generation treatment is envisioned as a single-injection therapy, offering unparalleled convenience for patients. In recognition of the potential impact and significance of this research, IISER has secured approval from the Indian Council of Medical Research for a comprehensive three-year project dedicated to scaling up this groundbreaking therapy.
